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Summary
Background New designs of female condom have been developed to reduce costs and improve acceptability. To secure 
regulatory approvals, clinical studies are needed to verify performance. We aimed to assess the functional performance 
and safety of three new condom types—the Woman’s Condom, the VA worn-of-women (wow) Condom Feminine, 
and the Cupid female condom—against the existing second-generation female condom (FC2).
Methods We did a randomised controlled, non-inferiority, four-period crossover trial at three sites in Shanghai, China, 
and one site in Durban, South Africa, between May 1, 2011, and Jan 31, 2012. Participants aged 18–45 years who were 
sexually active, monogamous, not pregnant, and not sex workers, were eligible for inclusion if they were literate, had no 
known allergies to the study products; used a reliable, non-barrier method of contraception, and had no visible or reported 
sexually transmitted infections. We used a computer-generated randomisation sequence with a Williams square design 
of size four to assign patients (1:1:1:1) to the FC2 control device, or the Woman’s, VA wow, or Cupid condoms, with 
12 potential allocations. Randomisation was stratiﬁ ed by site. Participants were not masked to condom type, but allocation 
was concealed from study investigators. The primary non-inferiority endpoints were total clinical failure and total female 
condom failure, with a non-inferiority margin of 3%. Women were asked to use ﬁ ve of each condom type and were 
interviewed after use of each type. We also assessed safety data for each type. We did both per-protocol and intention-to-
treat analyses. We calculated frequencies and percentages for each failure event and estimated diﬀ erences in performance 
with a generalised estimating equation model. This study is registered, number DOH-27-0113-4271.
Findings 616 women were assessed for eligibility, of whom 600 were randomly assigned to condom-type order (30, 120, 
and 150 women in the three sites in China, and 300 women in the site in South Africa). 572 women completed follow-
up, with at least one condom of each type. Total female condom failure was 3·43% for FC2, 3·85% for the Woman’s 
Condom (diﬀ erence 0·42%, 90% CI –1·42 to 2·26), 3·02% for VA wow (–0·42%, –1·86 to 1·32), and 4·52% for 
Cupid (1·09%, –0·60 to 2·78); total clinical failure was 2·88%, 3·05% (0·17%, –1·48 to 1·81), 2·49% (–0·25%, 
–1·75 to 1·26), and 3·87% (0·99%, –0·55 to 2·52), respectively. Only two (<1%) participants, in South Africa, reported 
serious adverse events, unrelated to use of the study products.
Interpretation Non-inferiority was shown for all condom failure events for the three new devices versus the FC2, 
within the predeﬁ ned margin.
Funding Universal Access to Female Condoms (UAFC).
Introduction
Evidence is scarce about the eﬀ ect of choice of 
contraceptive method on increased uptake of methods; 
however, a systematic review1 in 2006 supported the 
theory that increased contraceptive choice for women is 
associated with increased uptake and better health 
outcomes (eg, lower pregnancy rates and fewer sexually 
transmitted infections [STIs]). Furthermore, women 
continue use of their chosen contraceptives to a greater 
degree than do those who are denied a choice.2 The female 
condom is a barrier method that could increase choice for 
women worldwide. Although distribution of female 
condoms continues to increase worldwide, doubling 
from 25 million to 50 million units between 2007 and 
2010, it is substantially lower than that for male condoms, 
and accounts for only 0·19% of global condom 
procurement.3 In 2011, the female condom was identiﬁ ed 
by the Reproductive Health Supplies Coalition as one of 
several underused reproductive health technologies that 
could expand choice in reproductive health and family 
planning programmes, add value to the method mix, and 
respond to the needs of various clients.4
Several new female condoms in the ﬁ nal stages of 
development, or that have recently become available, aim 
to reduce unit cost or improve acceptability.5 The ﬁ rst-
generation female condom (FC1), made by the Female 
Health Company, was approved by the US Food and Drug 
Administration (US FDA) in 1993 (now discontinued). 
Classiﬁ ed as class 3 medical devices by the US FDA, the 
regulatory process for female condoms is more complex 
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than that for male condoms. This diﬀ erence was 
compounded by the absence, until 2011, of an 
international standard to verify the quality of new devices. 
To secure regulatory approvals, including WHO–UNFPA 
prequaliﬁ cation, manufacturers need to do clinical 
studies to verify the performance of new designs of 
female condoms. In 2009, the US FDA approved the 
second-generation female condom (FC2) on the basis of 
results of a non-inferiority study6 in which the 
investigators compared the functional performance of 
FC2 with that of FC1 with respect to condom failure 
events. Studies of the functional performance of condoms 
typically collect detailed data for small numbers of 
condom uses (ﬁ ve to ten uses) in a short period of time 
(4–6 weeks). Conversely, studies of condom eﬀ ectiveness 
for prevention of pregnancy should be done over at least a 
6 month period and are far more costly to do than are 
functional performance studies. Studies of contraceptive 
eﬀ ectiveness were not needed for US FDA approval for 
FC2 and no studies of contraceptive eﬀ ectiveness have 
been published for FC2. If new female condoms are non-
inferior to FC2 in function, choices will increase and 
individual needs can be considered for women wanting to 
prevent pregnancy and STIs and HIV. We assessed the 
functional performance and safety of three new female 
condom designs: the Woman’s Condom, the VA worn-of-
women (wow) Condom Feminine, and the Cupid female 
condom versus the FC2 device. 
Methods
Study design and participants
We undertook this four-period, randomised, non-
inferiority, crossover, clinical trial between May 1, 2011, 
and Jan 31, 2012, at three centres in Shanghai, China (the 
Shanghai Institute of Planned Parenthood Research 
Hospital and two aﬃ  liated family planning districts—
XuJiahui and Xuhui), and one centre in Durban, South 
Africa (an urban reproductive health clinic). Participants 
aged 18–45 years who were sexually active, monogamous, 
and not practising sex workers, were eligible for inclusion 
if they had no known allergies to the study products 
(latex, synthetic latex, polyurethane); used a reliable, non-
barrier method of contraception; and had no STIs (as 
established by pelvic examination and use of a syndromic 
diagnostic approach). Participants could be novice or 
experienced users of condoms, but had to be literate 
because take-home condom logs were used to obtain 
data. We excluded pregnant women (established by urine 
 Figure 1: Trial proﬁ le
The numbers of women withdrawing after period one were two for the sequence CWVF, three for FVWC, none for VCFW, and three for WFCV; after period two were three, two, one, and two, 
respectively; and for period three were three, two, one, and two, respectively. C=Cupid. W=Woman’s Condom. V=VA worn-of-women. F=second-generation female condom (FC2).
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pregnancy test). Participants from the South African site 
were similar in proﬁ le and recruited from the same site 
as that in the study used to establish the comparative 
performance of the reference condom (FC2) to the 
predicate device, FC1.6 Participants gave written informed 
consent before screening and enrolment. 
The study was approved by the institutional review 
boards of the University of Witwatersrand Human 
Research Ethics Committee in South Africa and the 
Ethical Committee of Shanghai Institute of Planned 
Parenthood Research in China. The study was also 
approved by the National Population and Family Planning 
Commission (NPFPC) in China and by the provincial, 
district, and local departments of health in South Africa. 
Male partners were informed of the study through use of 
a fact sheet, which explained the purpose of the study and 
provided information about the study products and their 
role in the research. Our study methods are based on the 
recommendations of WHO–UNFPA.7
Randomisation and masking
We used a computer-generated randomisation sequence 
(SAS version 9.38) to assign patients to one of 12 se-
quences of condom use (ﬁ gure 1). Randomisation was 
stratiﬁ ed by site. We used a Williams design, which 
consisted of the random construction of a Williams 
square (ﬁ rst step) and the random allocation of women 
to the treatment sequences, independently at each site 
(second step).9 These sequences were balanced for 
period and treatment, and each treatment had a 
diﬀ erent preceding treatment. To ensure such balance, 
the Williams design uses block sizes of four in a Latin 
square.
To devise a simple and eﬀ ective method of concealment, 
we designed a scratch card per participant, containing 
the allocated treatment sequence, whereby each code for 
a given condom type was concealed beneath a separate 
foil square. For each card, research staﬀ  would remove 
(scratch) the foil corresponding to the visit number 
printed above the square, thereby revealing the next visit 
allocation in the sequence. This novel adaption of an 
existing technology had not been previously reported for 
concealment of the allocation sequence in a randomised 
crossover trial. The development and use of the cards for 
this trial has been reported elsewhere.10 Participants were 
not masked to condom type because the designs are all 
quite distinct and required product-speciﬁ c training.
Procedures
Our primary objective was to compare the functional 
performance of the four types of female condom within 
the selected study populations (ﬁ gure 2). The FC2 was 
the control device, because the predicate device (FC1) 
ceased production in 2009. Each condom product was 
shipped by the manufacturer to Family Health 
International (now FHI 360) for quality assurance testing 
to ensure that products were of the quality speciﬁ ed by 
The second-generation female condom (FC2)
In 2009, the FC2 replaced the polyurethane first-generation female 
condom (FC1; trade names include Reality and Femidom), which had 
been available since 1993. FC2 is similar in specification and 
appearance to FC1, but is made of synthetic nitrile rubber latex. FC2 
has a flexible inner ring to insert the device and keep it in place during 
use. A ring at the open end lies flat across the genital area. FC2 was 
regarded as acceptable for bulk procurement by all UN agencies in 2007. 
In 2009, FC2 was approved by the US Food and Drug Administration.
The Woman’s Condom
The Woman’s Condom, designed and developed by the Program for 
Appropriate Technology in Health (PATH), is made of polyurethane. 
The condom sheath is tucked into an insertion capsule that dissolves 
after insertion. The four foam dots on the body of the condom ensure 
internal stability. The condom is not pre-lubricated and is supplied with 
a water-based lubricant. Licensed to the Dahua Medical Apparatus 
Company (Shanghai, China), the Woman’s Condom received the 
CE Mark of the European Union in 2010, and the approval of the 
Shanghai Food and Drug Administration in 2011.
The VA wow Condom Feminine
The VA wow condom (Medtech Products, India) is made of natural 
rubber latex and encases a medical-grade sponge at the closed end. 
The sponge is used for insertion and the outer anchoring structure has 
a triangular-shaped frame. The condom is lubricated with silicone oil. 
The device carries the CE Mark of the EU, and has approvals from the 
India Drug Control Authority and the Ministry of Health in Brazil.
The Cupid female condom
The Cupid condom (Cupid, India), manufactured in India, is available in 
some European and African countries. Made of natural rubber latex, the
condom has an octagonal outer frame and is inserted with a medical-
grade sponge, which also holds the condom in place during use. The 
device is pre-lubricated with silicone oil and comes in natural latex and 
pink colours. The Cupid condom is the only scented condom of all those 
assessed. The condom holds the CE Mark of the EU, is prequalified by 
WHO–UN Population Fund and registered by the India Drug 
Control Authority.
A
B
C
D
Figure 2: Description of study products
Panel 1: Deﬁ nitions of failure modes
• Total clinical failure: the number of female condoms that clinically break or slip, or that are 
associated with misdirection, invagination, or any additional failure modes identiﬁ ed in 
the risk assessment, which result in reduction of the protective function of the condom
• Total condom failure: a female condom for which a non-clinical breakage, clinical 
breakage, or slippage occurs, or that is associated with misdirection, invagination, 
or any additional failure modes identiﬁ ed in the risk assessment 
• Clinical breakage: breakage of the condom during sexual intercourse or during withdrawal 
of the female condom from the vagina (potential adverse clinical consequences)  
• Non-clinical breakage: breakage noticed before intercourse or occurring after 
withdrawal of the condom from the vagina (no potential adverse clinical consequences)
• Total breakage: the number of all  condom breakages at any time before, during, 
or after sexual intercourse; includes both clinical and non-clinical breakages  
• Slippage: when a female condom slips completely out of the vagina during sexual 
intercourse  
• Misdirection: vaginal penetration whereby the penis is inserted between the condom 
and the vaginal wall
• Invagination: when the external retention feature of the female condom is partly or 
fully pushed into the vagina during sexual intercourse  
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the manufacturer and met International Organization 
for Standardization (ISO 25841-2011) requirements.7
The primary endpoints were self-reported total 
clinical failure and total female condom failure. 
Additionally, we assessed the component failure events 
of clinical breakage, non-clinical breakage, total 
breakage, slippage, misdirection, and invagination.11 
Panel 1 shows the deﬁ nitions of each failure mode 
analysed. We also collected data for safety and 
acceptability. Failure events are recognised by WHO 
and other regulatory agencies.
Our secondary objectives were to assess the safety and 
acceptability of each condom type and to compare 
acceptability endpoints between the four types, with 
superiority hypotheses. We measured and assessed 
safety of each device according to number, severity, 
relatedness, and duration of adverse events. We collected 
standard acceptability measures and these data will be 
reported elsewhere.
In this study, each woman was asked to use ﬁ ve of each 
of the four condom types and to complete a condom log 
at home after each condom use. After women completed 
use of each condom type, they returned to the clinic to be 
interviewed about their experiences. Condom logs were 
used to obtain data for condom function and safety. 
We used interviewer-assisted questionnaires to gather 
acceptability and preference data.
Statistical analysis
We calculated the power to show non-inferiority 
obtained for diﬀ erent sample sizes, starting with a 
minimum of 200 couples completing the study as 
recommended by ISO 25841-2011 for functionality 
studies of acute failure events with female condoms 
based on self-reports.12 We assumed a total failure rate 
of 4% for FC2 as reported from previous research,6 and 
a correlation between uses of 0·15, as reported for male 
condoms.13 With 3% as a clinically determined margin 
of non-inferiority and a signiﬁ cance level of 5% for the 
hypothesis of non-inferiority, 500 women (250 per 
country) completing the study would provide 98% 
power in each country. We expected a non-completion 
rate of 15% (ie, 85% would provide relevant follow-up 
data for at least one condom of each type); therefore, we 
increased the sample size to 600 women (300 per 
country). In the power calculation, we adjusted for 
various comparisons with the Bonferroni criterion.14
The hypothesis for the primary endpoints of total 
clinical failure and total female condom failure and their 
component failure events, was that each of the three new 
condoms was non-inferior to FC2 for the rate of events 
within a margin of 3·0%.
The main analysis for primary and secondary endpoints 
was according to the assigned condom use sequence in the 
subset of participants who provided relevant follow-up data 
for at least one condom of each type (per-protocol analysis). 
We did an additional analysis with women with complete 
or incomplete condom series (one to four condom types, 
one to ﬁ ve uses each; data not shown). This additional 
analysis was by intention to treat, but with exclusion of 
three participants for whom no data about condom 
function were available. All analyses were stratiﬁ ed by 
country.
To show non-inferiority, the upper limit of the two-sided 
90% CI for the diﬀ erence in the occurrence of events (new 
condom minus FC2) needed to be below 3·0%. If non-
inferiority was shown, we tested superiority at a 5% level 
of signiﬁ cance using a two-sided 95% CI.
We analysed primary endpoints with a generalised 
estimating equation approach assuming a binomial 
China
(n=300)
South Africa
(n=272)
Total
(N=572)
Age (years)
Mean (SD) 36·3 (5·68) 27·9 (6·29) 32·3 (7·30)
Min–max 21–45 18–44 18–45
Ethnic group
Asian (Chinese) 299 (>99%) 0 299 (52%)
Black 0 271 ( >99%) 271 (47%)
Coloured 0 1 (<1%) 1 (<1%)
White 1 (<1%) 0 1 (<1%)
Completed years of school
0–5 4 (1%) 2 (<1%) 6 (1%)
6–10 79 (26%) 24 (9%) 103 (18%)
11–15 160 (53%) 244 (90%) 404 (71%)
16–20 57 (19%) 2 (<1) 59 (10%)
Primary occupation
Health or medical 39 (13%) 5 (2%) 44 (8%)
None or unemployed 34 (11%) 134 (49%) 168 (29%)
Oﬃ  ce, public service, or government 104 (35%) 4 (1%) 108 (19%)
Sales 33 (11%) 12 (4%) 45 (8%)
Self employed or other 51 (17%) 21 (8%) 72 (13%)
Student 50 (18%) 50 (9%)
Teacher or lecturer 6 (2%) 3 (1%) 9 (2%)
Technical 13 (4%) 1 (<1) 14 (2%)
Unskilled labour 20 (7%) 42 (15%) 62 (11%)
Number of living children
0 20 (7%) 50 (18%) 70 (12%)
1 266 (89%) 117 (43%) 383 (67%)
2 14 (5%) 70 (26%) 84 (15%)
≥3 35 (13%) 35 (6%)
Civil status
Married or living together 298 (99%) 62 (23%) 360 (63%)
Not married and not living together 2 (<1%) 210 (77%) 212 (37%)
Duration of relationship with current spouse or partner
<1 year 4 (1%) 17 (6%) 21 (4%)
1–5 years 61 (20%) 156 (57%) 217 (38%)
6–10 years 57 (19%) 58 (21%) 115 (20%)
>10 years 178 (59%) 41 (15%) 219 (38%)
Data are number of individuals (%) unless otherwise indicated.
Table 1: Baseline sociodemographic characteristics of the main analysis population by country and overall
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distribution, and with an identity link function, including 
type of condom in the model at the couple-use level and 
deﬁ ning couples as clusters, to take into account the 
crossover nature of the design. We used an 
interchangeable error structure within couples and 
adjusted results by multiplicity with Scheﬀ é’s method.13 
This trial is registered, number DOH-27-0113-4271.
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writ ing of 
the report. MEB, GP, JP, RG, and CJ had full access to the 
primary data. All other authors (JAS, JW, YZha, and YZho) 
had access to the data collected in their own country. All 
authors had ﬁ nal responsibility for the publication.
Results
Figure 1 shows the trial proﬁ le. 600 women were enrolled 
in the study (300 per country). 572 (95%) women 
completed the study with each woman using at least one 
condom of each of the four types. These women comprise 
the main analysis population. Only three women, in 
South Africa, did not use any condom.
Chinese participants were older than participants from 
South Africa (table 1). Women in both countries were 
well educated, with 72% in China and 90% in South 
Africa having more than 10 years of schooling (table 1). 
Most Chinese participants were married or living with 
their partners, whereas most South African participants 
were not married or residing with their partners (table 1). 
188 (63%) of 300 Chinese participants and 272 (100%) of 
South African participants had used male condoms 
previously, whereas 39 (14%) of South African women 
had previous experience with female condoms compared 
with no participants in China.
11 350 female condoms were used in this study by 
women in the main analysis population (2838 Cupid, 
2850 FC2, 2827 VA wow. and 2835 Women’s Condoms).
Table 2 shows the mean failure rate and failure diﬀ erence 
of Cupid, VA wow, and Woman’s Condom compared 
with FC2 for both countries combined. Non-inferiority 
was shown, within the non-inferiority margin, for all 
failure modes for the three new devices versus FC2 (data 
not shown) and for the two countries combined (table 2 
and ﬁ gure 3). The additional analysis done with women 
with complete or incomplete condom series provided 
similar results (data not shown).
We noted no evidence of superiority for any of the new 
condoms compared with FC2 in any of the failure modes 
(table 2).
Overall, the occurrence of adverse events and medical 
problems for the enrolled population was low (data not 
shown). Only two (<1%) participants in South Africa 
reported serious adverse events, unrelated to use of the 
study products. 27 (5%) adverse events were reported in 
the 597 women using at least one condom at least once. 
Adverse events occurred in fewer than 1% (range 
0·14–0·38%) of participants for each condom type. 
Adverse event reports were vaginal burning (ﬁ ve with VA 
wow in China); vaginal itching (one with Cupid, one with 
FC2, and one with Women’s Condom in South Africa); 
Mean failure 
rate (%)
Failure diﬀ erence (%) p value
Diﬀ erence 
with FC2
90% CI 95% CI
Clinical breakage*
Cupid 0·10 NE NE NE ··
VA wow 0·08 NE NE NE ··
WC 0·00 NE NE NE ··
FC2 0·25 NE NE NE ··
Non-clinical breakage
Cupid 0·66 0·04 –0·61 to 0·69 –0·69 to 0·77 0·9991
VA wow 0·53 –0·09 –0·52 to 0·33 –0·57 to 0·38 0·9586
WC 0·74 0·12 –0·41 to 0·65 –0·47 to 0·71 0·9557
FC2 0·62 (Ref) ·· ·· ··
Total breakage
Cupid 0·77 –0·05 –0·76 to 0·66 –0·84 to 0·74 0·9984
VA wow 0·67 –0·14 –0·67 to 0·38 –0·73 to 0·44 0·9226
WC 0·84 0·02 –0·57 to 0·60 –0·63 to 0·67 0·9999
FC2 0·82 (Ref) ·· ·· ··
Invagination
Cupid 1·21 0·03 –0·85 to 0·91 –0·95 to 1·01 0·9999
VA wow 0·99 –0·20 –1·17 to 0·77 –1·28 to 0·89 0·9684
WC 0·47 –0·72 –1·46 to 0·03 –1·55 to 0·12 0·1247
FC2 1·18 (Ref) ·· ·· ··
Misdirection
Cupid 1·22 0·62 –0·12 to 1·37 –0·21 to 1·46 0·2264
VA wow 1·19 0·58 –0·21 to 1·37 –0·30 to 1·47 0·3309
WC 1·13 0·53 –0·31 to 1·37 –0·41 to 1·47 0·4759
FC2 0·60 (Ref) ·· ·· ··
Slippage
Cupid 1·48 0·50 –0·41 to 1·42 –0·52 to 1·53 0·5979
VA wow 0·43 –0·55 –1·17 to 0·07 –1·25 to 0·14 0·1760
WC 1·28 0·30 –0·64 to 1·24 –0·75 to 1·35 0·8880
FC2 0·98 (Ref) ·· ·· ··
Total clinical failure
Cupid 3·87 0·99 –0·55 to 2·52 –0·73 to 2·70 0·4614
VA wow 2·49 –0·25 –1·75 to 1·26 –1·92 to 1·43 0·9823
WC 3·05 0·17 –1·48 to 1·81 –1·67 to 2·01 0·9957
FC2 2·88 (Ref) ·· ·· ··
Total female condom failure
Cupid 4·52 1·09 –0·60 to 2·78 –0·80 to 2·98 0·4552
VA wow 3·02 –0·42 –1·86 to 1·32 –2·05 to 1·51 0·9809
WC 3·85 0·42 –1·42 to 2·26 –1·64 to 2·47 0·9553
FC2 3·43 (Ref) ·· ·· ··
NE=not estimable. Cupid=Cupid female condom. VA wow=VA worn-of-women Condom Feminine. WC=Woman’s 
Condom. FC2=second-generation female condom. 2-sided 90% CIs for non-inferiority hypothesis at α=5% and 2-sided 
95% CIs for superiority hypothesis, with p va lues, adjustment for multiplicity by Scheﬀ é’s method. *Estimated as mean 
proportions of 75 women each because generalised estimasting equation model did not converge.
Table 2: Mean failure rate and failure diﬀ erence of Cupid, VA wow, and Woman’s Condom in relation to 
FC2, complete condom series population, for both countries
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vaginal pain or swelling (two with Cupid, two with FC2, 
one with VA wow in South Africa); penile itching, burning, 
rash, or swelling (one with FC2, two with VA wow, and 
one with Women’s Condom in South Africa); general rash 
(one with Women’s Condom in China); and unknown, 
unclear, or unrelated rash (three with Cupid, two with 
FC2, three with VA wow, and one with Women’s Condom 
in South Africa). All events resolved without sequelae.
Discussion
Although individual failure rates vary by country and 
condom type, the three new devices assessed in this 
study were non-inferior to the reference condom (FC2) 
within the non-inferiority margin for all the functional 
parameters. The rates of total clinical failure, total female 
condom failure, and component failure reported were 
expected and are consistent with ﬁ ndings from previous, 
similarly undertaken studies.6,15–17 Furthermore, the 
failure results reported in this study were from two 
culturally diverse study populations. That the results are 
similar between South Africa and China attests further to 
the validity of the ﬁ ndings. These data show that 
clinically, the new female condoms assessed function in 
a similar way to the FC2. Data from this study have been 
used to ﬁ nalise the dossier submitted to WHO–UNFPA 
for the Cupid condom and resulted in its prequaliﬁ cation 
for public sector procurement in June, 2012.18 The 
manufacturer of the Woman’s Condom (Dahua, China) 
will use these data to ﬁ nalise their dossier and 
submissions to WHO–UNFPA and US FDA. The VA 
wow condom is under review by WHO–UNFPA; 
however, manufacture of the product is suspended, 
possibly related to change of ownership of the factory.
On the basis of ﬁ ndings from this trial, these new 
female condoms could be important players in 
contraception and STI prevention. The availability of new 
types of female condoms will provide donors and users 
with more options and could reduce the unit price of 
devices.4 Although prediction of how far the price of 
female condoms will reduce in the future is not possible, 
the Reproductive Health Supplies Coalition has 
published information comparing diﬀ erent unit costs to 
the donor funded public sector, indicating that the Cupid 
female condom, which was prequaliﬁ ed in 2012, will be 
sold at a lower price per unit than FC2.4 However, studies 
of contraceptive eﬀ ectiveness and those showing 
eﬀ ectiveness or reductions in STI incidence with these 
new female condoms are still needed.
Contraception is one strategy that can have an eﬀ ect on 
and improve maternal health by reducing unplanned 
pregnancy. In 2009, estimates showed that if all women 
who wanted to avoid pregnancy used modern 
contraceptives, the number of unintended pregnancies 
in developing countries would fall from 75 million to 
22 million annually.19 Reasons for unmet need for 
contraception go beyond simple access to methods, and 
are attributable to a combination of factors including 
personal and cultural issues, religious restrictions, 
concern about side-eﬀ ects, health concerns, and scarcity 
of knowledge. For this reason, the need to have a range of 
available contraceptive methods is crucial (panel 2).
A limitation of our study was that masking of the 
participants and research staﬀ  to the products was not 
possible because the products all diﬀ er in appearance. 
We used allocation concealment to ensure that this 
limitation was minimised. This study was based on only 
self-reported measures of condom use. Reporting of 
condom use by participants can be inaccurate compared 
with more reliable methods such as exposure to prostate-
speciﬁ c antigen, which provides a more objective 
Figure 3: Estimates of the risk diﬀ erence between failure of new female condoms and failure of FC2, for the 
primary outcomes of TFCF and TCF, showing the results for non-inferiority
TFCF=total female condom failure. VA wow=VA worn-of-women. TCF=total clinical failure. FC2=second-generation 
female condom.
 0·42% (–1·42 to 2·26)
 –0·42% (–1·86 to 1·32)
 1·09% (–0·60 to 2·78)
 0·17% (–1·48 to 1·81)
 –0·25% (–1·75 to 1·26)
 0·99% (–0·55 to 2·52)
TFCF–Woman’s Condom
TFCF–VA wow
TFCF–Cupid
TCF–Woman’s Condom
TCF–VA wow
TCF–Cupid
New condom better FC2 better
Risk diﬀerence (90% CI)
–4·00 –3·00 –2·00 –1·00 0 1·00 2·00 3·00 4·00
Panel 2: Research in context
Systematic review
We searched PubMed between Jan, 2000, and Oct, 2012, for 
articles published up to November, 2012, with the search 
terms “female condom functional performance”. No 
randomised trials, using any of the three new types of female 
condom—the Woman’s Condom, the VA worn-of-women 
(wow) Condom Feminine, and Cupid—were identiﬁ ed, aside 
from one randomised, non-inferiority trial6 used to establish 
the functional performance of the second-generation female 
condom, FC2, compared with the predicate device (FC1).
Interpretation
This study is the ﬁ rst randomised trial of the functionality of 
female condoms in China. The new female condoms were 
non-inferior to the reference condom (FC2) within a margin 
of 3% failure for all the functional parameters. This is the ﬁ rst 
trial that has provided important function data for these 
devices and has been used to compile evidence for 
WHO–UNFPA prequaliﬁ cation. Because of this trial, the Cupid 
condom has already been approved by WHO–UNFPA and is 
available for public sector procurement. Manufacturers of the 
other devices are using these data in their ongoing 
applications to regulatory authorities. Access to various types 
of female condoms could improve choice for women in need 
of a contraceptive method or of dual protection against 
pregnancy and infection.
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measure of condom failure.20 However, techniques that 
use prostate-speciﬁ c antigen are more expensive and 
study procedures more complex.
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